Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 113Recruiting 82Completed 50Not yet recruiting 15Terminated 13Withdrawn 3Suspended 2Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma 1HTLV-I Infections 1

Interventions

Specimen Handling 31Magnetic Resonance Spectroscopy 19Biopsy 16Cyclophosphamide 10venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Vincristine 5Etoposide 5fludarabine phosphate 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiation 4Injections 4Doxorubicin 4Cisplatin 4fludarabine 3X-Rays 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Radiosurgery 3Prednisone 3Leucovorin 3Irinotecan 3Ipilimumab 3Fluorouracil 3Educational Status 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Lenalidomide × 1 year × Clear all
NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06348147 2026-05-04

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

UNC Lineberger Comprehensive Cancer Center

Phase 2 Suspended
39 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡